within Pharmacolibrary.Drugs.ATC.A;

model A10AE56
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9999999999999998e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.004,
    k12             = 0.4,
    k21             = 0.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AE56</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Insulin degludec and liraglutide is a fixed-ratio combination drug used in the treatment of type 2 diabetes mellitus in adults. Insulin degludec is a long-acting basal insulin analog, and liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The combination is approved and used to improve glycemic control in adults with type 2 diabetes inadequately controlled with basal insulin, GLP-1 receptor agonist, or oral antidiabetic drugs.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for adults based on component drugs (insulin degludec and liraglutide), subcutaneous administration, as PK data for the fixed combination are not directly published.</p><h4>References</h4><ol><li><p>Ziebarth, J, et al., &amp; Mara Mainardes, R (2024). Optimized LC-MS/MS method for quantifying insulin degludec and liraglutide in rat plasma and Tissues: Application in pharmacokinetics and biodistribution. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 1234 124015–None. DOI:<a href=\"https://doi.org/10.1016/j.jchromb.2024.124015\">10.1016/j.jchromb.2024.124015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38266609/\">https://pubmed.ncbi.nlm.nih.gov/38266609</a></p></li><li><p>Scheen, AJ, &amp; Mathieu, C (2018). [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)]. <i>Revue medicale de Liege</i> 73(10) 526–532. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30335259/\">https://pubmed.ncbi.nlm.nih.gov/30335259</a></p></li><li><p>Zhai, J, et al., &amp; Ge, Z (2020). Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application. <i>Biomedical chromatography : BMC</i> 34(10) e4921–None. DOI:<a href=\"https://doi.org/10.1002/bmc.4921\">10.1002/bmc.4921</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32537846/\">https://pubmed.ncbi.nlm.nih.gov/32537846</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AE56;
